Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients
BACKGROUND: To identify whether circulating levels of angiogenesis-related factors may be predictive of bevacizumab efficacy in pre-treated metastatic colorectal cancer (mCRC) patients. METHODS: Pre-treatment serum levels of 24 cytokines were measured using a multiplex bead assay (MBA) in 32 pre-...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | info:eu-repo/semantics/article |
| Language: | eng |
| Published: |
Nature
2014
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/10171/36169 |
| _version_ | 1793400391770046464 |
|---|---|
| author | Abajo, A. (Ana) Boni, V. (Valentina) Lopez, I. (Inés) Gonzalez-Huarriz, M. (Marisol) Bitarte, N. (Nerea) Rodriguez, J. (Javier) Zarate, R. (Ruth) Bandres, E. (Eva) Garcia-Foncillas, J. (Jesús) |
| author_facet | Abajo, A. (Ana) Boni, V. (Valentina) Lopez, I. (Inés) Gonzalez-Huarriz, M. (Marisol) Bitarte, N. (Nerea) Rodriguez, J. (Javier) Zarate, R. (Ruth) Bandres, E. (Eva) Garcia-Foncillas, J. (Jesús) |
| author_sort | Abajo, A. (Ana) |
| collection | DSpace |
| description | BACKGROUND:
To identify whether circulating levels of angiogenesis-related factors may be predictive of bevacizumab efficacy in pre-treated metastatic colorectal cancer (mCRC) patients.
METHODS:
Pre-treatment serum levels of 24 cytokines were measured using a multiplex bead assay (MBA) in 32 pre-treated mCRC patients treated with irinotecan plus bevacizumab-based salvage therapy. Macrophage-derived chemokine (MDC), interleukins (ILs) 8 and 6 levels were also validated by enzyme-linked immunosorbent assay (ELISA) at different time points during therapy.
RESULTS:
Higher epidermal growth factor (EGF) and MDC baseline levels (2.2- and 1.4-fold, respectively) and lower IL-10, IL-6 and IL-8 levels (0.2-, 0.6-, and 0.6-fold, respectively, P<0.05) were observed in patients responding to therapy. Baseline levels of these five serum factors compose a risk signature that may define the subset of patients most likely to benefit from bevacizumab-based therapy in terms of response rate and survival times. A positive correlation was found between MBA and ELISA results (P<0.01). Treatment exposure increased MDC and had opposite effects on IL-8 levels, which were decreased (P<0.05).
CONCLUSION:
This study suggests that a set of inflammatory and angiogenesis-related serum markers may be associated with the efficacy of bevacizumab-containing regimen. |
| format | info:eu-repo/semantics/article |
| id | oai:dadun.unav.edu:10171-36169 |
| institution | Universidad de Navarra |
| language | eng |
| publishDate | 2014 |
| publisher | Nature |
| record_format | dspace |
| spelling | oai:dadun.unav.edu:10171-361692020-03-04T02:25:19Z Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients Abajo, A. (Ana) Boni, V. (Valentina) Lopez, I. (Inés) Gonzalez-Huarriz, M. (Marisol) Bitarte, N. (Nerea) Rodriguez, J. (Javier) Zarate, R. (Ruth) Bandres, E. (Eva) Garcia-Foncillas, J. (Jesús) Bevacizumab Serum biomarkers Colorectal cancer Multiplex bead assays BACKGROUND: To identify whether circulating levels of angiogenesis-related factors may be predictive of bevacizumab efficacy in pre-treated metastatic colorectal cancer (mCRC) patients. METHODS: Pre-treatment serum levels of 24 cytokines were measured using a multiplex bead assay (MBA) in 32 pre-treated mCRC patients treated with irinotecan plus bevacizumab-based salvage therapy. Macrophage-derived chemokine (MDC), interleukins (ILs) 8 and 6 levels were also validated by enzyme-linked immunosorbent assay (ELISA) at different time points during therapy. RESULTS: Higher epidermal growth factor (EGF) and MDC baseline levels (2.2- and 1.4-fold, respectively) and lower IL-10, IL-6 and IL-8 levels (0.2-, 0.6-, and 0.6-fold, respectively, P<0.05) were observed in patients responding to therapy. Baseline levels of these five serum factors compose a risk signature that may define the subset of patients most likely to benefit from bevacizumab-based therapy in terms of response rate and survival times. A positive correlation was found between MBA and ELISA results (P<0.01). Treatment exposure increased MDC and had opposite effects on IL-8 levels, which were decreased (P<0.05). CONCLUSION: This study suggests that a set of inflammatory and angiogenesis-related serum markers may be associated with the efficacy of bevacizumab-containing regimen. 2014-07-17T10:08:15Z 2014-07-17T10:08:15Z 2012-07-10 info:eu-repo/semantics/article https://hdl.handle.net/10171/36169 eng info:eu-repo/semantics/openAccess application/pdf Nature |
| spellingShingle | Bevacizumab Serum biomarkers Colorectal cancer Multiplex bead assays Abajo, A. (Ana) Boni, V. (Valentina) Lopez, I. (Inés) Gonzalez-Huarriz, M. (Marisol) Bitarte, N. (Nerea) Rodriguez, J. (Javier) Zarate, R. (Ruth) Bandres, E. (Eva) Garcia-Foncillas, J. (Jesús) Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients |
| title | Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients |
| title_full | Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients |
| title_fullStr | Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients |
| title_full_unstemmed | Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients |
| title_short | Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients |
| title_sort | identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients |
| topic | Bevacizumab Serum biomarkers Colorectal cancer Multiplex bead assays |
| url | https://hdl.handle.net/10171/36169 |
| work_keys_str_mv | AT abajoaana identificationofpredictivecirculatingbiomarkersofbevacizumabcontainingregimenefficacyinpretreatedmetastaticcolorectalcancerpatients AT bonivvalentina identificationofpredictivecirculatingbiomarkersofbevacizumabcontainingregimenefficacyinpretreatedmetastaticcolorectalcancerpatients AT lopeziines identificationofpredictivecirculatingbiomarkersofbevacizumabcontainingregimenefficacyinpretreatedmetastaticcolorectalcancerpatients AT gonzalezhuarrizmmarisol identificationofpredictivecirculatingbiomarkersofbevacizumabcontainingregimenefficacyinpretreatedmetastaticcolorectalcancerpatients AT bitartennerea identificationofpredictivecirculatingbiomarkersofbevacizumabcontainingregimenefficacyinpretreatedmetastaticcolorectalcancerpatients AT rodriguezjjavier identificationofpredictivecirculatingbiomarkersofbevacizumabcontainingregimenefficacyinpretreatedmetastaticcolorectalcancerpatients AT zaraterruth identificationofpredictivecirculatingbiomarkersofbevacizumabcontainingregimenefficacyinpretreatedmetastaticcolorectalcancerpatients AT bandreseeva identificationofpredictivecirculatingbiomarkersofbevacizumabcontainingregimenefficacyinpretreatedmetastaticcolorectalcancerpatients AT garciafoncillasjjesus identificationofpredictivecirculatingbiomarkersofbevacizumabcontainingregimenefficacyinpretreatedmetastaticcolorectalcancerpatients |